Analyst Ratings For TherapeuticsMD (NASDAQ:TXMD)
Today, Deutsche Bank AG initiated coverage on TherapeuticsMD (NASDAQ:TXMD) with a Buy.
There are 7 buy ratings on the stock.
The current consensus rating on TherapeuticsMD (NASDAQ:TXMD) is Buy (Score: 3.00) with a consensus target price of $17.17 per share, a potential 219.68% upside.
Some recent analyst ratings include
- 7/21/2017-Deutsche Bank AG initiated coverage with a Buy rating.
- 7/17/2017-Cowen and Company Reiterated Rating of Outperform.
- 7/11/2017-CIBC Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 7/11/2017-Oppenheimer Holdings, Inc. Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 5/24/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 5/10/2017-Cantor Fitzgerald Reiterated Rating of Overweight.
Recent Trading Activity for TherapeuticsMD (NASDAQ:TXMD)
Shares of TherapeuticsMD closed the previous trading session at 5.37 up +0.02 0.37% with 2,046,268 shares trading hands.